DIA Exhibitor Gallery. You are invited to visit the following company booths at DIA.
You are invited to visit these DIA 2012 booths:
Booth No. 1539Catalentwww.calatent.com
Phone: +1 888 SOLUTION (7658846)
E-mail:solutions@catalent.com
Booth No. 1733Cromsourcewww.cromsource.com
Phone: +39 045 8222811
E-mail:cromsource@cromsource.com
Booth No. 2725ERTwww.ert.com
Contact: Tom Avery
Phone: 215-972-0420
E-mail: eresearch@ert.com
Booth No. 1951Forte Research Systemswww.forteresearch.com
Contact: Brian Wulff
Phone: 608-826-6000
E-mail: Allegro@ForteResearch.com
Booth No. 1148Globalcare Clinical Trialswww.globalcarect.com
Phone: 847-282-3280
E-mail: info@globalcarect.com
Booth No. 2112LabCorpwww.labcorp.com/clinicaltrials
Contat: Shailesh Maingi
Phone: 877-788-8861
E-mail: clintrialssales@labcorp.com
Booth No. 2441REGISTRAT-MAPIwww.registratmapi.com
Phone: 800-381-7878
E-mail: info@registratmapi.com
Booth No. 2533Spectra Clinical Research www.spectraclinicalresearch.com
Phone: 800-517-7157
E-mail: sales.spectraclinicalresearch@fmc-na.com
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
March 31st 2025Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to intravenous Keytruda.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.